Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod

• Main Authors: Qiudi Jiang (Author), Yuchen Zhang (Author), Dan Duan (Author), Sylvie Retout (Author), Ruchi Upmanyu (Author), Katerina Glavini (Author), Miriam Triyatni (Author), Yonghong Zhu (Author), Joseph F. Grippo (Author), Yuyan Jin (Author)
• Format: Book
• Published: Wiley, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Ruzotolimod (Toll‐like receptor 7 (TLR7) agonist, RG7854) is an oral, small molecule immuno‐modulator activating the TLR 7 and is being evaluated in patients with CHB. As with other TLR7 agonists, the study drug‐related adverse events of flu‐like symptoms have been reported in some particip...